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Goodpasture's epitope in development of experimental autoimmune
glomerulonephritis in rats. The Goodpasture's epitope (GP) has recently
been localized to the last 36 AA of the non-collagenous (NC1) domain of
the a3 chain of type IV collagen [a3(IV)]. Since a3(IV) induces glomer-
ulonephritis (GN) in rats and rabbits, the purpose of the present study was
to determine if the GP epitope itself could induce GN. We immunized rats
with synthetic peptides of GP epitope, 36-mer, alone or as protein
conjugates. Rats immunized with bovine GBM served as positive controls.
Peptide immunized rats developed high titer antibodies to peptides, but
only unconjugated 36-mer induced antibody against human and bovine
GBM, but not to rat GBM. Acidic residues and the full length 36-mer were
important in production of GBM reactive antibodies. Positive controls
developed antibody to GBM without reactivity against 36-mer, had IgG
and fibrin on the basement membrane, GN and proteinuria. Kidney eluted
antibody was reactive with rat, bovine, and human GBM but not 36-mer.
GN rat lymphocytes underwent blast transformation to GBM but not
peptide, and peptide immunized animals responded only to the respective
peptides. None of the animals immunized with GP peptide epitope,
despite the development of anti-peptide antibodies or anti-GBM antibod-
ies, developed any in vivo fixation of antibody to the GBM, abnormal
proteinuria, or GN. The present study shows that the GP epitope is
sufficient to induce an immune response to the epitope, but it is not
sufficient to induce GN. This demonstrates that other factors or epitopes
are important in the pathogenicity of GBM induced GN in this model.
These remain to be delineated.
Glomerulonephritis (GN) in humans associated with antibodies
to the glomerular basement membrane (GBM) presents as a
spectrum of diseases [1]. These range from asymptomatic GBM
deposits with pulmonary disease to rapidly progressive glomeru-
lonephritis (RPGN) in the absence of pulmonary symptoms, to
the extreme presentation of classic Goodpasture's syndrome with
RPGN and pulmonary hemorrhage. The antigenic specificity of
the pathogenic antibody to kidney or lung basement membrane
does not appear to be the determinant of the clinical presentation
of pulmonary hemorrhage, but rather the presence or absence of
insults to the lungs, such as smoking [2—4]. The most common
manifestation of anti-GBM disease is either RPGN or Goodpas-
ture's syndrome, which usually progresses rapidly to death or
end-stage renal disease requiring dialysis or transplantation [5].
Transplant patients are at risk of developing recurrent disease in
the graft with consequent loss of the transplant [6, 7]. Type IV
collagen in the kidney, lung and several other organs are unique
since they are comprised of a1 and a2 chains, but also chains
recently defined as a3 through a6 [8—121. Type IV collagen
appears to contain the epitope(s) responsible for anti-GBM
disease in humans as demonstrated by reactivity of sera from
patients with these diseases to the non-collagenous (NCI) domain
of type IV collagen [13—151. Most of this reactivity is directed to
the a3(IV) chain of the NC1 domain, but not against other chains
of GBM collagens [16—18].
The auto-antibodies which bind to Goodpasture's epitope have
been peptide mapped to the last 36 amino acids (AA) of a3(IV) [16].
The Goodpasture's epitope is cryptic, being exposed upon disasso-
ciation of the hexamer of NC1 domains with acid, guanidium
hydrochloride, and other disassociative agents [15, 19]. Furthermore,
monoclonal antibodies directed to a3(IV) recognize subfractions of
bovine and rat GBM [20] which produce experimental autoimmune
glomerulonephritis (EAG) in rats [20]. Basement membrane anti-
gens lacking chains found in GBM induce antibodies in rats to
basement membrane structures; however, they do not result in
proteinuria or GN [21]. Further, dimers of a3(IV) but not other NC1
domains can produce GN in rabbits [221, and rats (R. Kalluri,
personal communication). Finally, there is a high degree of homol-
ogy betveen human and rat a3(IV), including the last 36 AA which
are almost identical [23]. These findings suggest that the epitope(s)
responsible for clinical anti-GBM disease is localized to kidney
type(IV) collagen basement membrane components, that a3(IV)
collagen contains the epitope, and that the carboxy terminal 36 AA
may well contain the nephritogenic epitope(s).
Since EAG in WKY rats can be induced by GBM antigen
containing collagen chains but not by basement membrane lacking
these chains, the present experiments test the hypothesis that the
region of a3(IV) defined by peptide mapping to contain the
Goodpasture's epitope is itself capable of inducing EAG in the rat
model [21, 24]. Failure to induce EAG would suggest that an
epitope other than the 36-mer associated with Goodpasture's
epitope is responsible for EAG in the rat model, or that the 36-
mer containing Goodpasture's epitope may be sufficient to induce
marker antibodies but may require additional factor(s) for induc-
tion of GN. The findings of the present study suggest that the
latter pertains, at least in the rat model.
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Methods
Materials
GBM. Human and bovine kidneys were obtained at necropsy or
from a local abattoir, and rat kidneys from animals sacrificed in
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Fig. 1. Amino acid sequence of peptides used to immunize rats. The Goodpasture's epitope is contained within residues 198 to 233 of the a3(IV) NCI chain.
The number of animals in each group is presented. The approximate predicted percent binding for Goodpasture's sera by various peptides is provided in
the last column (per Kalluri et al [161). KLH is the abbreviation for keyhole limpet hemocyanin. Acidic residues are indicated by an asterisk.
the Department of Comparative Medicine. Kidneys were frozen
at —70°C until use and then glomeruli isolated by differential
sieving as previously described [24, 25]. GBM isolated by sonica-
tion was digested with type VII collagenase (Sigma), and the
resultant solubilized GBM (csGBM) was lyophilized and used as
the immunizing antigen and for ELISA and immunoblotting. The
term "csGBM" refers to bovine preparations unless otherwise
specifically indicated.
Hexamer. Dissociation of the NCI hexamer (globular domain of
type IV collagen) appears to be necessary for optimal exposure of
Goodpasture's epitope [15, 19]. Since our standard immunogen is
csGBM containing other components of GBM, one experiment
was performed with isolated NCI hexamer to confirm that the
nephritogenic antigen was related to this region of the GBM
rather than other constituents of the GBM. Hexamer was isolated
as described by Wieslander et al from bovine csGBM [19]. After
dialysis against 2 M urea, 0.05 M Tris-HCI, pH 7.5, csGBM was
chromatographed on a DE52 (Whatman) ion exchange column
equilibrated with the same buffer. The globular domain, which
does not bind, was dialyzed against 2 M urea, 0.05 M Tric-HCI, pH
9.0 and chromatographed on a second DE52 column in the same
buffer. Bound hexamer was eluted with a 0 to 0.2 M NaCI gradient,
concentrated and used to immunized rats, 100 .rg/animal by our
standard protocol.
Animals
Male WKY rats weighing 200 grams were obtained from Harlan
Sprague Dawley, maintained under standard conditions in the
Vivarium and fed standard chow.
Synthesis of peptides
The published sequence of the human a3col(IV) NC1 domain
was used to synthesize the peptides used in these experiments
[26]. Since our previous work strongly suggested a key role for
cellular immunity in pathogenesis [24], we analyzed the AA
sequence of a3(IV) to select short peptides which might elicit a
T-cell response with minimal antibody production. Amphipathic
plots were analyzed to select those most likely to be antigenic
T-cell sites. Of these, peptide 91R3 (Fig. 1) fell within the terminal
36AA of the cs3(IV) region described by Kalluri et al as containing
Goodpasture's epitope [16]. We further selected the 5 mer and 12
mer peptides when 91R3 failed to produce disease. When neither
the 5-mer nor 12-mer produced disease (or antibody), we synthe-
sized the full 36-mer to use alone or after protein conjugation.
The peptides were acetylated on the amino terminus and ami-
dated on the carboxyl terminus. The last peptide designated
"16-mer" comprises the carboxy terminal 16 AA with an acety-
lated amino terminus and free carboxyl terminus to assess the
effect of a free-COOH rather than -NH2 on disease induction.
Peptides were synthesized using 9-fluorenylmethyloxycarbonyl
chemistry on a Bioresearch 9600 automated peptide synthesizer
[27]. AA were coupled to the nascent peptide chain primarily
using 1-hydroxybenzotriazole active esters or if necessary symmet-
ric anhydrides. Cysteinyl residues were protected with acet-
amidomethyl groups that are stable to the conditions of the
cleavage and deprotection procedure [28]. The degree of coupling
was quantitated with ninhydrin assay of each coupling cycle [29].
Following cleavage and deprotection of the peptide from the
resin, the crude peptide product was desalted by chromatography
on Sephadex G-50 and then subjected to final purification by
reverse phase high pressure liquid chromatography. The purity of
the product was assessed by amino acid analysis on a Beckman
System Gold amino acid analysis system and mass analysis on a
Finnigan LaserMat mass spectrometer.
Immunization procedures
EAG develops in 100% of rats immunized by our standard
protocol: 20 j.rg rat, bovine or human GBM suspended in 0.1 M
acetic acid or after reduction, and alkylation, that is, iodoacet-
amide, or 1:40 /3 mercaptoethanol plus Bordetella pertussis intra-
peritoneally [24]. Antigen is emulsified 1:1 with CFA H37Ra and
given as a single footpad injection in 0.1 ml volume. Rats were
divided into groups to receive various types of immunization by
standard protocol, substituting peptide for csGBM as indicated.
Group I rats were immunized with 100 .rg of 36-mer. Group II was
immunized with 36-mer conjugated to keyhole limpet hemocyanin
(KLH) by the same regimen as described in Group I. Conjugation of
peptide to carrier proteins (KLH and ovalbumin, (ova) was
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accomplished using 1-ethyl-3-(3-di methiaminopropyl) carbodiim-
ide (EDC) [30]. Peptide (1 mg/mi) was dissolved in deionized
water, EDC added to a final concentration of 10 mg/mi, and the
pH adjusted to 5.0. After five minutes, an equal volume of carrier
protein was added to give a final molar ratio peptide to carrier
protein of 40:1. Molecular weights of carrier proteins used in
calculations: KLH 1,000,000; ova 45,000. Solutions were stirred
for two hours at room temperature in a siliconized flask, then 1.0
M sodium acetate added to give a final pH of 4.2. The solution was
stirred again for one hour, then dialyzed against PBS at 4°C
overnight. Controls in this group received KLH with CFA. Group
III rats received 16-mer, 50 jig/rat by standard protocol. Group IV
rats were immunized with bovine csGBM. Group V rats were
immunized with rat csGBM by standard protocol rather than
bovine csGBM used for all other csGBM immunizations. Group
VI rats were immunized by standard protocol using bovine
hexamer.
Positive control animals (Group IV), as well as negative control
animals, (standard protocol without antigen) were included within
each peptide immunization experiment. Abnormal proteinuria
and circulating anti-GBM antibodies appear by three to four
weeks in GBM immunized rats with EAG.
Total urinwy protein (TUP)
Animals were placed in metabolic cages and 24-hour urine
samples were collected weekly for TUP determinations. The latter
were done using 3% sulfosalicylic acid with bovine serum albumin
(BSA) as standard. [24] The upper limit of normal for 24 hour
TUP in rats in our laboratory is 10 mg [311. Animals were followed
for six weeks.
Histopathology
After the fifth urine collection for TUP, animals were sacrificed
and sections of kidney taken for examination. For light micros-
copy, tissue was fixed in 10% buffered formalin and 3 jim sections
were examined after staining with hematoxylin and eosin [24, 25].
Immunofluorescence studies of kidney sections were performed
using commercial mono-specific fluorescein labeled anti-sera to
rat IgG, C3 and fibrin (Cappel) [24, 25, 31]. The intensity of the
deposits was semiquantitatively graded as 0 to 4+ [24, 25, 31].
Indirect immunofluorescence was performed on normal kidney
tissue obtained in the operating room from patients having a
nephrectomy and were snap frozen immediately in dry ice isopen-
tane. Rat kidney used for indirect fluorescence was perfused with
50 ml of warm phosphate buffered saline (PBS) containing 1%
BSA. Indirect assays of sera were performed at dilutions of 1:40 to
1:100 on 4 jim kidney sections as previously described [24, 251.
Antibody assays
Sera from normal control subjects and from patients with
Goodpasture's syndrome, and experimental animals were exam-
ined by indirect immunofluorescence and by ELISA using Immu-
nolon II plates (Dynatech Laboratories, Inc., Alexandria, VA,
USA) coated with csGBM or peptide at a concentration of 10
jig/mi. Controls included buffer alone, blanks without second
antibody and omission of antigen. Positive and negative sera were
assayed. For competitive ELISAs, sera were preincubated over-
night at 4°C with csGBM or 36 mer as described in Results (Fig.
2), and ELISAs were then performed. ELISAs were all run in
duplicate.
Eluate
Kidneys from nephritic and CFA control rats were eluted by the
potassium iodide method and the antibodies used for ELISA and
immunoblotting [32]. Briefly, 20 rat kidneys were homogenized
and washed six times with PBS by centrifugation at 2000 x g at
4°C. The pellet was resuspended in 20 ml of 2.5 M potassium
iodide in Tris-HC1 buffer, pH 9.0 and rocked for one hour at room
temperature. After centrifugation at 10,000 X g at 4°C for 20
minutes, the supernatant was collected and dialyzed extensively
against PBS at 4°C. One percent BSA was added to stabilize
eluted immunoglobulin.
Immunoblotting
SDS-PAGE was performed using 8 to 22% gradient gels as
described by Laemmli [331. Samples included csGBM and ova-36
mer conjugate. Reduced and unreduced samples were separated
electrophoreticaliy, transferred to nitroceliulose paper, blocked
with milk for two hours at room temperature and then various
sera diluted 1:100 in 0.05 M PBS were overlaid for one hour.
Bound IgG was demonstrated using a chemiluminescence system
(Amersham) with various film exposure times to optimize banding
visualization.
Antigen-specific lymphocyte proliferation
Draining popliteal lymph nodes were harvested aseptically and
dispersed into single cell suspensions in DMEM medium supple-
mented with 1% sodium pyruvate, 1% non-essential amino acids,
1% 200 mst glutamine, 100 U penicillin, 100 jig/mi streptomycin,
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Fig. 2. Binding of sera from patients with Goodpasture's syndrome to
human GBM and 36-mer peptide. Sera from nine different patients with
clinical Goodpasture's syndrome were examined by ELISA with plates
coated with human csGBM () or 36-mer peptide (LI). Corrected for
normal serum background. *P < 0.01.
Goodpasture's sera
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Fig. 3. Competition of Goodpature's sera by 36
mer peptide and csGBM. Goodpasture's serum
competitive binding assay of human csGBM (A)
and bovine csGBM (B) coated plates with
increasing amounts of 36-mer (_*_) or bovine
csGBM (—U—). Expressed as percent inhibition.
5 X 10 M 2-mercaptoethanol and 10% heat-inactivated fetal calf
serum (Gibco, Gaithersburg, MD, USA). Cells were layered on
Lymphoprep (Nygaard Company, Norway) separated, and
washed three times in DMEM. Cells were enumerated by tiypan
blue exclusion and cultured at a concentration of 5 X io cells per
well in a total of 200 1.d in 96 well flat-bottom microtiter plates
(Costar, Cambridge, MA, USA). Concanavalin A was used at a
concentration of 4 ag/ml as a positive control, and medium
without antigen for background. Cultures were incubated at 37°C
in 5% CO2 for 72 hours and then pulsed with 1 iCi of 3H-
thymidine and cultured for an additional 16 hours. Lymphocyte
proliferation assays were done in triplicate with 50 to 200 pg/mI
csGBM and 10 to 100 !.LM concentrations of peptide. The amount
of cell-associated thymidine incorporation was expressed as
counts per minute (CPM) minus background counts, delta CPM
(CPM). A stimulation index (ratio of antigen stimulated to
medium thymidine incorporation) of  2.0 was considered signif-
icant.
Statistical method
Data are expressed as the mean SEM. All data are analyzed by
the Student's t-test and analysis of variance [251.
Results
ELISA binding of Goodpasture's auto-antibodies to csGBM and
36-mer
Sera from nine patients with clinical pulmonary hemorrhage,
RPGN, anti-GBM disease, and positive circulating antibodies by
standard ELISA and indirect immunofluorescence, were assayed
for antibodies against human csGBM and 36-mer (Fig. 2). All
patient sera were positive against the csGBM and 36-mer in
ELISA. Differences in binding are likely related to the linearity of
the 36-mer sequence versus native csGBM and reduced number
of intra-molecular disulfide bonds [16, 17]. Since Goodpasture's
sera are known to have a spectrum of specificities to various
regions of GBM as well as to different components of a1(IV) [18,
34, 35], studies were done to compete positive sera with 36-mer
using an ELISA assay with human and bovine csGBM as substrate
on plates. Anti-GBM antibody positive serum reacted strongly
with both bovine and human GBM antigen, and both 36-mer and
bovine GBM inhibited positive Goodpasture's sera in a dose
dependent fashion (Fig. 3). The 36-mer inhibition plateaued in
each assay at concentrations above 8 jIM/mi (30 to 40% inhibition)
while increasing quantities of bovine GBM incrementally inhib-
ited positive Goodpasture's sera. As expected, bovine GBM
competed more efficiently in ELISA's performed with bovine
csGBM as the coating antigen than when human GBM was used,
with essentially complete inhibition at 5,000 jig/mI of bovine
csGBM. The plateau of inhibition with 36-mer with both the
human and bovine csGBM substrate suggests that available
antibody directed to the 36-mer epitope was completely bound at
concentrations of 8 jiM/mI and greater of 36-mer. Thus, synthetic
36-mer peptide bound sera from all of the positive Goodpasture's
patients and competed with native antigen in ELISA.
Immunization with Goodpasture 's epitope
Since the last 36 AA of a3(IV) have been shown to contain the
highest antibody binding capacity for Goodpasture's serum [16],
and cs3(IV) NCI would appear to be the nephritogenic antigen in
this rat model induced with GBM, we immunized rats to attempt
to induce disease with this peptide. The results of experiments are
presented in the tables and figures. Table 1 contains the ELISA of
experimental sera. Table 2 describes the clinicopathology of the
direct and indirect immunofluorescence, TUP excretion in 24
hours, and the presence or absence of EAG. Figure 4 is the
immunoblot analysis of experimental sera versus ovalbumin36
mer (ova-36 mer) conjugate, and Figure 5 contains the quantita-
tive TUP excretion.
Rats immunized with 36-mer peptide by standard protocol
developed a vigorous antibody response to 36-mer and human and
bovine GBM. However, there was no abnormal proteinuria, no
antibody reactive to rat GBM, and no evidence of EAG.
0 8 40 200 1000 5000
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Table 1. ELISA of experimental sera from animals immunized with 36-mer, 16-mer, or csGBM
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Experimental group Immunizing antigen (N)
Plate antigen
36-mer 36-mer-ova KLH 16-mer csGBM
I
II
III
IV
36-mer
36-mer-KLH
16-mer
csGBM
10
8
3
11
2.04 0.1OC
1.99 0.13a
0.64 0.25
0.22 0.03
2.10 0.11
2.41 0.07 2.20 0.02
2.26 0.09
0.14 001b
2.22 0.04
0.19 002h
0.56 0.03C
0.06 0.02c
0.09 0.00C
1.92 0.15
Abbreviation is KLH, keyhole limpet hemocyanin.
P < 0.01 vs. csGBM, 16-mer
' P < 0.01 vs. 16-mer, 36-mer
P < 0.01 vs. 36-mer, csGBM
Table 2. Clinicopathologic findings in rats immunized with peptide or
csGBM
Experimental
group (N)
Immunizing
antigen
.Direct
IgG/
fibrina Gn' TUP
Indirect
kidney"
Human Rat
I 10 36-mer — — — +++ —
II 8 36-mer-KLH — — — —
III 3 16-mer — — — — —
IV 18 csGBM +1+ + + ++++ —
C Renal tissue in immunized rates
h EAG, experimental autoimmune glomerulonephritis
TUP, Total urinary protein
d Sera from immunized rats examined by indirect fluorescence on
normal human and rat kidney
I
.1
a) )i E
_j (.0 (00) c)
Ca2
a) .5 G)
E 0
2 ow
I I I
We reasoned that cross linking the peptide to a carrier protein
might enhance its immunogenicity. Therefore, 36-mer was cou-
pled to KLH and animals were immunized with the peptide-
carrier protein or carrier protein alone. These animals developed
a strong antibody response to 36-mer and the carrier protein, but
not to GBM in vitro or in vivo, nor GN nor abnormal proteinuria.
Influence of carboxy terminus
69—
The previous experiments had been performed with 36-mer
that was acetylated at the amino terminus and amidated at the
carboxyl terminus. Since cross linking via carbamylation destroys
carboxyl termini and resulted in failure to elicit an antibody
response compared to peptide alone with BME, we next con-
structed a peptide comprising the terminal 16 AA of a3(IV) with
an acetylated amino terminal end and a free carboxy terminus.
This portion of the final 36 AA of cs3(IV) accounts for 79% of the
Goodpasture's serum binding capacity observed with Goodpas-
ture's peptide epitopes [16]. Immunization of rats with this 16-mer
resulted in the development of high titer antibodies to the peptide
and to 36-mer in ELISA (free peptide) but not Western blot
(conjugated peptide). There was no antibody reactivity to csGBM
in ELISA, nor to human, bovine or rat kidney by indirect
fluorescence. None of these animals developed antibody on the
GBM, abnormal proteinuria or GN.
Control rats
None of the CFA negative control rats developed antibody or
disease. Positive controls, bovine csGBM immunized rats, all
developed high titer circulating antibody to GBM in ELISA and
Western blot which fixed to human and bovine GBM by indirect
fluorescence on kidney tissue sections. These rats had IgU depos-
Fig. 4. Immunoblot of sera from rats immunized with 36 mer or csGBM.
Immunoblot of sera from various experimental groups versus ova-36 mer
conjugate, 1 g/lane, SDS-PAGE. Size marker (kDa) is indicated. Sera
used for blotting are listed above each lane. Last lane, normal rat serum.
ited along the GBM, fibrin deposits with proliferative GN and
crescents as previously described, and progressive proteinuria
(Fig. 5). Rats immunized with hexamer all developed GN indis-
tinguishable from those immunized with csGBM. Despite the
presence of antibody in kidney biopsies of the rats and the
formation of circulating antibodies reactive with human and
bovine GBM, circulating antibodies did not bind to normal
Fig. 5. Development of abnormal total urinaty
protein (TUP) in rats immunized with bovine
csGBM or peptides. None of the rats in the
experimental groups immunized with peptides
developed abnormal proteinuria (> 10 mg/24
hr). Symbols are: (U 91R3; (#) 5-mer; (•) 12-
6 mer; (+) 16-mer; (*) 36-mer; () 36-mer-KLH;(A) csGBM. < 0.01 versus CFA controls or
peptide immunized rats.
perfused rat kidney. However, eluates from nephritic kidneys
were positive by indirect fluorescence on rat, human, and bovine
kidney, and in ELISA and Western blot against all three species
GBM. Renal eluates were unreactive with ova-36-mer in Western
blots (Fig. 4). Therefore, in Experiment V, rats were immunized
with rat csGBM by standard protocol. All animals developed
typical EAG with heavy proteinuria indistinguishable from EAG
observed in bovine and human GBM immunized rats. Circulating
antibodies bound to bovine and human GBM by Western blot,
ELISA, and indirect fluorescence. In contradistinction to bovine
and human csGBM immunized rats, animals immunized with rat
csGBM now displayed circulating antibody which bound to rat
GBM in vitro.
In vitro thymidine incorporation
Blast transformation studies were performed using lymph node
cells derived from an animal immunized against bovine csGBM.
As described previously, rat lymphocytes underwent blast trans-
formation in response to human and bovine GBM (Table 3) [24],
but not to 36-mer or 16-mer as the stimulating antigen. Each
peptide elicited blastogenesis to cells from rats immunized to the
peptide, but these cells did not respond to csGBM.
Discussion
The present studies document that synthetic peptides spanning
the last 36 AA of the NC1 domain of a3(IV) bind Goodpasture's
antibody and competitively inhibit the binding of Goodpasture's
sera to GBM in a dose dependent fashion. csGBM consists mostly
of monomers and dimers of the various NC1 domains of type IV
collagen, and individual Goodpasture's sera have different speci-
ficities for other components of csGBM than a3(IV) NC1 alone
[18, 34, 35]. In addition, the tertiary structure of native csGBM
cannot be reproduced by synthetic peptide. Nonetheless, the
inhibition of Goodpasture's sera by 36-mer in the present studies
was comparable to that reported by Kalluri et al using a compet-
itive binding assay of peptide versus purified a3 NCI domain [16].
In those studies, the percent inhibition of this region of a3(IV)
NC1 was approximately 35 to 50%, similar to the degree of
inhibition observed here. Thus our peptides appear to contain the
Goodpasture's epitope as described by others [16].
Evidence cited suggests that the nephritogenic antigen for
Goodpasture's syndrome and EAG in rats resides in the NC1
domain of the a3(IV) collagen chain. Antibody binding studies of
isolated a3 NC1 monomers and dimers and peptide mapping
imply that the terminal 36AA of NCI cs3(IV) may be the
pathogenic antigen [22]. However, others have suggested that
additional regions of a3(IV) may be targeted by anti-GBM
autoantibodies, especially at the amino terminal portion of a3(IV)
NC1 [36]. Peptide binding studies of Kalluri et al [22] and the
competitive binding studies presented here (Fig. 3), also support
the possibility that other epitopes may be involved.
Although monomers of a3(IV) NC1 have not been shown to be
pathogenic, isolated dimers of a3(IV) NC1 induce EAG while
basement membrane preparations lacking a3(IV) are non-nephri-
togenic [21, 22]. Since immunization of rats with human, bovine,
or rat csGBM results in the production of severe EAG and the
terminal 36AA of a3(IV) NCI contains the Goodpasture's
epitope [20, 24], we anticipated that this peptide would produce
EAG. Immunization with 36-mer peptide alone or conjugated to
KLH did result in high titer antibodies to 36-mer as well as any
carrier protein but only animals immunized with 36-mer peptide
without KLH developed antibodies cross reactive to bovine and
human GBM.
Cross linking of 36-mer to KLH by the carbodiimide method,
which utilizes only the carboxyl termini of acid residues [30],
induced high titer antibody against 36-mer and conjugate. How-
ever, this completely blocked development of antibodies cross
reactive with GBM. The last 36 AA of a3(IV) NC1 contains four
acidic residues available for conjugation by the carbodiimide
method. We routinely prepare our synthetic peptides with an
amidated carboxyl terminus, so three interior acidic residues
would be available for cross linking. Since carboxy terminus
amidated 36-mer failed to induce EAG despite development of
antibodies to GBM, and because cross linking to carrier protein by
carbamylation alters the acidic residues and abolished binding to
GBM, we postulated that the acid terminus might be key for a
nephritogenic antibody response. Further, most antibody binding
to the terminal 36 AA of a3(IV) NC1 is localized to the last 5 AA
with a carboxy terminus [16]. We therefore repeated immuniza-
tions using the terminal 16 amino acids with a carboxyl ending.
These animals developed a vigorous antibody response to peptide
but failed to develop antibodies to GBM or GN. The 16-mer
immunized rats did develop an antibody response to 36-mer in
ELISA, but this was low titer and was unreactive against ova-36-
mer conjugate in Western blot. Furthermore, 16-mer rats did not
produce antibodies to human and bovine GBM as seen with
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Table 3. Antigen specific proliferation of rat lymphocytes from animals
immunized with 36-mer, 16-mer, or csGBM
Condition
dCPMU
36-mer 16-mer csGBM
Medium 4,846 490 5,227 2,023 6,066 2,179
Bovine GBM 3,003 412
(0.6)
3,698 879
(0.7)
31,519 1,782
(5.2)
Human GBM NDC ND 26,393 1,826
(4.4)
36-mer 46,540 5,133
(9.6)
1,366 352
(0.3)
10,929 1,232
(1.8)
16-mer 5,828 1,713
(1.2)
14,560 2,486
(2.8)
5,826 1,990
(1.0)
a dCPM, delta CPM (antigen specific CPM minus background CPM)
Stimulation index, considered significant if  2.0, given in parenthesis
a ND, not done
36-mer rats. This implicates an important function for acidic
residues in the peptide induced antibody cross reactivity to human
GBM, but also suggests that the preceding 2OAA are involved in
this process as well. Presumably some type of conformational
change occurs when all four acidic residues are cross linked by
carbodiimide to KLH so resultant antibodies bind KLH and
36-mer but not human and bovine GBM. Restoration of the two
acidic residues alone in the 16-mer is not sufficient to restore
ability to elicit GBM cross reactive antibodies.
Antigen-specific lymphocyte proliferation
Previous phenotypic studies [241 strongly suggest a role for
cellular immunity in the production of this model. Animals have
renal infiltrates with macrophages and lymphocytes, display de-
layed hypersensitivity reactions to GBM, their mononuclear cells
undergo blast transformation to GBM, and development of EAG
is suppressed with cyclosporine A [24, 37]. In the present studies,
rats with EAG had mononuclear cell incorporation of tritiated
thymidine with csGBM, as previously described, but did not
respond to 36-mer or 16-mer. Rats immunized to 36-mer or
16-mer underwent blast transformation to the immunizing pep-
tides but not csGBM. Thus, not only did the peptides fail to elicit
antibody cross reactivity, but also did not produce any evidence of
cross reactive cellular immunity.
None of the different peptide immunizations, regardless of the
production or non-production of circulating antibody or the
development of cell mediated immunity to the immunogen,
resulted in the formation of antibodies in situ on GBM, any
abnormal proteinuria or any histologic abnormalities. However,
immunization of rats with native csGBM but not membrane
preparations lacking a3(IV) NC1 results in the development of
florid EAG with proteinuria [211. NCI hexamers also produced
EAG comparable to that induced with csGBM. This may be
resultant from our use of acetic acid in our immunization protocol
which dissociates the hexamer [15, 19], since Kalluri et al reported
that hexamer was not pathogenic in rabbits using non-dissociated
hexamer [22]. Presumably some type of insult to the GBM in
humans, such as hydrocarbon exposure, the effects of cell associ-
ated enzymes, etc., can expose and dissociate the hexamer,
initiating the autoimmune cascade culminating in Goodpasture's
syndrome. Eluates obtained from nephritic kidneys demonstrated
binding to human, bovine, and rat sections and to csGBM (control
eluate, 0.09 Ab units compared to nephritic eluate of 1.0 Ab
units405), but was negative in ELISA versus 36-mer (0.1 Ab units)
and ova-36-mer conjugate in Western blot. Failure of EAG serum
and eluate from nephritic kidneys to bind to 36-mer show that rats
immunized with csGBM do not have circulating antibody to the
peptide nor is antibody to the peptide bound in the kidneys on
resident 36-mer or a homologous protein in the rat GBM. Yet
immunization with rat csGBM produced identical disease to
human and bovine csGBM, now with circulating antibodies to rat
as well as human and bovine GBM. These observations demon-
strate that while cs3(IV) NC1 domain still remains a strong
candidate for the nephritogenic antigen in this rat model of FAG,
the synthesized 36-mer peptide containing Goodpasture's
epitope, as mapped by Goodpasture's sera, is not pathogenic.
Whether this is resultant from the linear nature of the synthesized
peptide, from post-translational modifications that occur to the
native protein in vivo, whether synergistic influences from other
molecule(s) or effector systems are required, if the epitope
required to produce EAG in rats is different from that in humans,
or if epitope spreading may be necessary, all remain to be
clarified.
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